JNJ-61178104
/ J&J
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 19, 2019
Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of JNJ-61178104, a Novel Tumor Necrosis Factor-Alpha and Interleukin-17A Bispecific Antibody, in Healthy Subjects.
(PubMed, J Clin Pharmacol)
- "The time to reach mean maximum serum total TNFα and total IL-17A concentrations appeared to be dose dependent across the 0.1 mg/kg to 10 mg/kg IV dose groups. All subjects who received active treatment were antidrug antibody positive after dosing with JNJ-61178104."
Clinical • Journal • PK/PD data
June 17, 2020
Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A.
(PubMed, MAbs)
- "These findings show that in vivo target engagement of monovalent bispecific antibody does not necessarily recapitulate that of the molar-equivalent dose of its bivalent parental antibody. Our results also offer valuable insights into the understanding of the pharmacokinetics/pharmacodynamics and target engagement of other bispecific biologics against dimeric and/or trimeric soluble targets in vivo."
Journal • Immunology • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • IL17A • TNFA
1 to 2
Of
2
Go to page
1